NIX1 Inhibitors
Chemical inhibitors of NIX1 function through various pathways to impede the protein's activity within cellular processes. Cyclosporin A employs a mechanism whereby it obstructs the function of calcineurin. The inhibition of this phosphatase is crucial since calcineurin is responsible for the activation of NFAT, a transcription factor that directly influences the expression of NIX1. Similarly, FK506, or Tacrolimus, forms a complex with FKBP12 that also results in calcineurin inhibition. This prevents the dephosphorylation and subsequent activation of NFAT, leading to a decrease in NIX1 expression. In contrast, Rapamycin, also known as Sirolimus, associates with FKBP12 but diverges in its target, focusing on the mTOR pathway. The inhibition of mTOR interferes with one of the regulatory pathways of NIX1, thus hindering the upregulation of the protein.
Continuing along the biochemical cascade, LY294002 and Wortmannin are inhibitors that target PI3K. By impeding the PI3K signaling, these inhibitors disrupt downstream actions including AKT and mTOR signaling, which are implicated in the regulation of NIX1 expression. PD98059 and U0126, on the other hand, act by selectively inhibiting MEK1/2 within the MAPK/ERK pathway. The MAPK/ERK pathway is another conduit through which NIX1 expression can be regulated. By blocking this pathway, these inhibitors contribute to the functional inhibition of NIX1. SB203580 specifically inhibits p38 MAPK, a kinase involved in cellular responses to stress, which can also affect NIX1 expression. SP600125 targets JNK, a kinase within the MAPK pathway, thus influencing the expression of NIX1 by obstructing the pathway's ability to regulate the protein.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A inhibits calcineurin, which is necessary for the dephosphorylation and activation of nuclear factor of activated T-cells (NFAT). NFAT is a transcription factor that can lead to the expression of NIX1. By inhibiting calcineurin, Cyclosporin A prevents NFAT activation, thus functionally inhibiting NIX1 by reducing its expression. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
FK506 binds to FKBP12, forming a complex that inhibits calcineurin similarly to Cyclosporin A. This inhibition prevents the activation of NFAT which is a crucial step in the upregulation of NIX1 expression. Therefore, FK506 functionally inhibits NIX1 by preventing the increase in its expression mediated by NFAT. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin forms a complex with FKBP12, but instead of affecting calcineurin, it inhibits the mammalian target of rapamycin (mTOR). mTOR is part of a signaling pathway that can lead to the upregulation of NIX1. By inhibiting mTOR, Rapamycin functionally inhibits the protein by preventing the pathway's contribution to NIX1 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). PI3K signaling is involved in multiple cellular processes, including those that can lead to the upregulation of NIX1. By inhibiting PI3K, LY294002 disrupts the pathway, thereby functionally inhibiting the upregulation of NIX1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another inhibitor of PI3K, leading to the disruption of the PI3K/AKT/mTOR pathway. This pathway is implicated in the regulation of NIX1. Thus, by inhibiting PI3K, Wortmannin functionally inhibits the protein NIX1 by preventing the PI3K/AKT/mTOR pathway's role in the upregulation of NIX1 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK1), which is part of the MAPK/ERK pathway. This pathway can regulate the expression of NIX1. By inhibiting MEK1, PD98059 functionally inhibits the protein NIX1 by blocking the MAPK/ERK pathway's contribution to its upregulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also an inhibitor of MEK1/2, preventing the activation of the ERK pathway. Since the MAPK/ERK pathway can regulate NIX1 expression, U0126 functionally inhibits NIX1 by impeding the pathway's activity that contributes to the protein's regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. The p38 MAPK pathway plays a role in cellular stress responses and can influence the expression of NIX1. By inhibiting p38 MAPK, SB203580 functionally inhibits NIX1 by blocking the pathway's role in stress-induced upregulation of the protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK pathway. JNK signaling can impact the expression of NIX1. By inhibiting JNK, SP600125 functionally inhibits NIX1 by obstructing the JNK pathway's influence on the protein's expression. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $74.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor which can influence apoptotic pathways. Since NIX1 is involved in the regulation of apoptosis, inhibition of caspases by Z-VAD-FMK can functionally inhibit the downstream effects of NIX1 by preventing apoptosis, a process in which NIX1 is implicated. | ||||||